Ziprasidone

Ziprasidone
Clinical data
Trade names	Geodon, others
AHFS/Drugs.com	Monograph
MedlinePlus	a699062
License data	US DailyMed: Ziprasidone;
Pregnancy; category	AU: C;
Routes of; administration	By mouth, intramuscular injection (IM)
Drug class	Atypical antipsychotic
ATC code	N05AE04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); US: ℞-only;
Pharmacokinetic data
Bioavailability	60% (oral) ; 100% (IM)
Metabolism	Liver (aldehyde reductase)
Elimination half-life	7 to 10 hours
Excretion	Urine and feces
Identifiers
	IUPAC name 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one;
CAS Number	146939-27-7 ;
PubChem CID	60854;
IUPHAR/BPS	59;
DrugBank	DB00246 ;
ChemSpider	54841 ;
UNII	6UKA5VEJ6X;
KEGG	D08687 ;
ChEBI	CHEBI:10119 ;
ChEMBL	ChEMBL708 ;
CompTox Dashboard (EPA)	DTXSID4023753 ;
ECHA InfoCard	100.106.954
Chemical and physical data
Formula	C21H21ClN4OS
Molar mass	412.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1Cc2c(N1)cc(Cl)c(c2)CCN3CCN(CC3)c4nsc5ccccc45;
	InChI InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) ; Key:MVWVFYHBGMAFLY-UHFFFAOYSA-N ;
	(verify)

Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It may be used by mouth and by injection into a muscle (IM). The intramuscular form may be used for acute agitation in people with schizophrenia.

Common side effects include tremors, tics, dizziness, dry mouth, restlessness, nausea, and mild sedation. Although it can also cause weight gain, the risk is much lower than for other atypical antipsychotics. How it works is not entirely clear but is believed to involve effects on serotonin and dopamine in the brain.

Ziprasidone was approved for medical use in the United States in 2001. The pills are made up of the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form is the mesylate, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder. In 2020, it was the 282nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.